EPGD co-delivery of doxorubicin and gemcitabine enhances activity in EpCAM-high tumour models with lower renal injury-associated readouts in a microfluidic co-culture platform.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42523119.
- Also identified by DOI 10.1039/d6lc00007j.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cytotoxic chemotherapy remains indispensable for many epithelial malignancies, yet gemcitabine (GEM) and doxorubicin (DOX) are constrained by a narrow therapeutic index and clinically significant toxicity. Here, we developed an epithelial cell adhesion molecule (EpCAM)-targeted DNA aptamer (EP)-based construct for co-delivery of GEM and DOX and evaluated its antitumour activity together with renal injury-associated readouts <i>in vitro</i>. A GEM-integrating EP construct (EPG) was generated by substituting seven cytidines with GEM residues, followed by DOX loading through intercalation into GC-rich regions to form EPGD. Mass spectrometry confirmed the expected molecular species, and DOX association with EP/EPG was supported by fluorescence quenching. ELONA-based analyses further showed that EPG retained EpCAM binding with a modest increase in apparent <i>K</i><sub>d</sub> relative to EP, while competitive ELONA supported preserved, competitively inhibitable EpCAM engagement under the tested conditions. In an evaporation-driven microfluidic self-perfusion chip, EPGD induced greater tumour cytotoxicity and more pronounced γ-H<sub>2</sub>AX formation than free drugs or single-drug aptamer formulations at matched nominal drug concentrations. In patient-derived intrahepatic cholangiocarcinoma organoids, EPGD reduced viability in a concentration-dependent manner. In a dual-compartment microfluidic chip operated under shared perfusion, HK-2 proximal tubular cells cultured on a kidney-derived decellularised extracellular matrix showed higher viability together with lower kidney injury molecule-1 (KIM-1) secretion and lactate dehydrogenase (LDH) release after EPGD treatment than after free GEM and DOX. Together, these findings indicate that EPGD integrates CI-supported GEM/DOX synergism demonstrated in A549 cells with preferential activity in EpCAM-high tumour models and is associated with lower renal injury-associated readouts in this <i>in vitro</i> microfluidic platform.